|Mr. Luc Tanguay M.Sc., C.F.A.||Pres, CEO & Non-Independent Director||N/A||N/A||59|
|Mr. Philippe Dubuc MBA||Sr. VP & CFO||284.6k||N/A||50|
|Mr. Jocelyn Lafond LL.B., L.L.M.||VP of Legal Affairs & Corp. Sec.||N/A||N/A||49|
|Mr. Christian Marsolais Ph.D.||Sr. VP & Chief Medical Officer||N/A||N/A||54|
|Ms. Lyne Fortin MBA, B.Pharm.||Sr. VP & Chief Commercial Officer||N/A||N/A||57|
Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. Its lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 10; Compensation: 9.